Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Professor calls for better clinical trials of antivirals
Cats suffering from FIV and FeLV require special management and care.

Review looks at antiviral use in retrovirus-infected cats

A leading professor in small animal medicine is calling for better clinical trials of antivirals following publication of a review into their use in retrovirus-infected cats.

Professor Katrin Hartmann, head of the clinic of small animal medicine at the LMU University of Munich, Germany, says that more well-designed clinical trials would improve judgement on treatment efficacy and side effects.

Antiviral chemotherapy is of increasing interest in veterinary medicine, but is still not commonly used.  The review, published in the Journal of Feline Medicine and Surgery, examines current literature on antiviral chemotherapy in retrovirus-infected cats, focusing on drugs that are currently available on the market, and therefore could potentially be used in cats.

Concluding the review, Professor Hartmann writes: 'Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses.

'Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown.
Therefore, it is very important that more well-designed double-blind, placebo-controlled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds.'

Feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) are among the most common infections affecting cats worldwide, but differ in their potential to cause disease. 
Cats suffering from FIV and FeLV require special management and care and, provided they receive this, can live for many years in good health.

In more severe cases, the advice is to consider incorporating antivirals into the treatment regime. Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HIV), based on the rationale that FIV and HIV are closely related.

FeLV is not as closely related to HIV, with the result that the available drugs have mostly been found to be less effective against this retrovirus.

 

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.